系统性红斑狼疮临床惰性的相关因素与结局:多中心LUNA队列研究
该历史性队列研究利用日本多中心LUNA队列365例基线前1年存在活动性疾病的SLE患者,按基线疾病活动度及1年内治疗强化状态分为非强化组(n=247)与强化组(n=118),并将临床惰性组(n=116,持续活动未强化)与非临床惰性组(n=249)比较。回归分析显示非强化与临床惰性均与损伤增加相关,临床惰性与总体及糖皮质激素相关损伤增加相关,并与多个领域生活质量下降趋势相关。作者结论认为避免临床惰性是治疗优先事项,需定期重新评估治疗策略。
要点
- 非强化治疗与糖皮质激素相关损伤增加幅度更大相关。
- 临床惰性与总体损伤及糖皮质激素相关损伤增加幅度更大相关。
- 羟氯喹使用及较少的联合免疫抑制剂预测治疗非强化;女性及更大损伤累积预测临床惰性。
核心结论
- 作者认为临床惰性可驱动损伤累积和生活质量恶化,避免临床惰性是治疗优先事项。
- 作者认为对老年患者、女性及损伤累积较大者定期重新评估治疗策略至关重要。
- 作者认为根据个体风险特征主动调整治疗可阻止临床惰性并改善长期结局。
研究设计与样本
- 历史性队列研究,使用日本多中心LUNA队列数据。
- 纳入基线前1年存在活动性疾病的365例SLE患者(SLE疾病活动指数评分>4或活动性胃肠道病变或溶血性贫血)。
- 按基线疾病活动度及1年内治疗强化状态分为非强化组(n=247)与强化组(n=118)。
- 临床惰性组(n=116)定义为持续活动性疾病且未强化治疗,与非临床惰性组(n=249,包括所有其他患者)比较。
- 采用回归分析评估预测因素及结局,包括损伤累积、疾病活动度、生活质量(QoL)和患者满意度。
主要发现
- 非强化与糖皮质激素相关损伤增加幅度更大相关。
- 临床惰性与总体损伤及糖皮质激素相关损伤增加幅度更大相关。
- 非强化和临床惰性与多个领域生活质量下降趋势相关。
- 羟氯喹使用及较少的联合免疫抑制剂预测治疗非强化。
- 女性及更大损伤累积预测临床惰性;较大年龄对两种结局显示相似但未达显著的趋势。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: This study aimed to identify predictors of clinical inertia in SLE management and to evaluate its impact on clinical outcomes. METHODS: A historical cohort study was conducted using data from the multicentre LUNA cohort in Japan. The 365 patients with active disease 1 year before baseline (SLE Disease Activity Index score >4 or active gastrointestinal lesions or haemolytic anaemia) were classified by baseline disease activity and treatment intensification status over 1 year into non-intensification (n = 247) vs intensification (n = 118) groups. Furthermore, the clinical inertia group (n = 116), defined as sustained active disease without intensification, was compared with the non-clinical inertia group (n = 249), which comprised all other patients. Regression analyses assessed predictors and outcomes, including damage accrual, disease activity, quality of life (QoL) and patient satisfaction. RESULTS: Non-intensification was associated with larger increases in glucocorticoid-related damage, while clinical inertia was linked to greater increases in overall and glucocorticoid-related damage. Non-intensification and clinical inertia correlated with a tendency towards reduced QoL across several domains. HCQ use and fewer concomitant immunosuppressants predicted non-intensification of treatment, whereas female sex and greater damage accrual predicted clinical inertia; older age showed similar but non-significant trends for both outcomes. CONCLUSION: Because clinical inertia can drive damage accrual and QoL deterioration, avoiding clinical inertia is a therapeutic priority. Regular reassessment of treatment strategy is essential for older patients, women and those with greater damage. Proactive tailoring of treatment to individual risk profiles can arrest clinical inertia and improve long-term outcomes.
引用
- Miyake H, Kida T, Yoshimi R, et al. Factors and outcomes related to clinical inertia in systemic lupus erythematosus: a multicentre LUNA cohort study. Rheumatology (Oxford). 2026. PMID: 40981511. doi:10.1093/rheumatology/keaf504
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。